Skip to content

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Validation Clinical Trial of the Efficacy and Safety of Vasopressin Injection in the Treatment of Distributed Shock Hypotension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Validation Clinical Trial of the Efficacy and Safety of Vasopressin Injection in the Treatment of Distributed Shock Hypotension

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061190
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distributed Shock Hypotension

Interventions

Experiment group:Norepinephrine + Vasopressin Injection

Sponsors

Department of Critical Care Medicine, West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. There is no gender limitation, and the age should be 18-80 years old (including the critical value); 2. Patients with distributed shock within 48 hours who have received fluid resuscitation, norepinephrine treatment dose of 0.2-1.0 µg/kg/min and duration >= 2h; 3. The mean arterial pressure should be 60-70mmHg, and the duration >= 2h; 4. Cardiac index > 2.3L/min/m2; Or the central venous oxygen saturation > 70%, and the central venous pressure > 8 mmHg; 5. Patients or their guardians are willing and able to provide written informed consent and abide by the trial protocol.

Exclusion criteria

Exclusion criteria: 1. Suffering from symptoms such as Raynaud's disease, systemic sclerosis or vasospasm; whooping cough or bronchospasm; acute mesenteric ischemia; aortic dissection or abdominal aortic aneurysm; malignancy; acute coronary syndrome requiring interventional therapy; End-stage liver and kidney failure; Severe cardiac insufficiency, or severe arrhythmia, or heart transplantation, or severe cardiac algal membrane disease, etc.

Design outcomes

Primary

MeasureTime frame
Laboratory tests;

Countries

China

Contacts

Public ContactYan Kang
kangyan@scu.edu.cn+86 18980601566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026